Forest Laboratories acquires rights to antiarrhythmic agent
Forest Laboratories has agreed a deal with Blue Ash Therapeutics to acquire global rights to a novel antiarrhythmic agent called azimilide.
The Rainforest Action Network said it would review its support for the Forest Stewardship Council, a forest products certification standard, over concerns regarding its certification of destructive logging operations.